SB527
Pharmaceutical Substance Manufacturing Grant Fund; created.
Status:
In Senate
Latest Action:
Feb. 10, 2026
Senate: Reported from Finance and Appropriations (14-Y 0-N)
Chief Patron:
Creigh Deeds (D)
Session:
2026 Regular Session
Summary
As Introduced. Pharmaceutical Substance Manufacturing Grant Fund.
Establishes the Pharmaceutical Substance Manufacturing Grant Fund to provide grant installment awards between July 1, 2026, and July 1, 2045, in an amount not to exceed $34 million per fiscal year and in an aggregate amount not to exceed $191,255,000 million, to a qualified company that (i) engages in the ... (More) manufacture of pharmaceutical substances, (ii) executes a memorandum of understanding with the Commonwealth, and (iii) is expected to make a capital investment of at least $4 billion and create and maintain at least 500 new full-time jobs. This bill is a recommendation of the MEI Project Approval Commission. (Less)-
Bill History
- 01/13/2026 - Senate: Prefiled and ordered printed; Offered 01-14-2026 26102905D
- 01/13/2026 - Senate: Referred to Committee on Education and Health
- 01/22/2026 - Senate: Rereferred from Education and Health to Commerce and Labor (14-Y 0-N)
- 01/22/2026 - Senate: Rereferred to Commerce and Labor
- 01/23/2026 - Senate: Fiscal Impact Statement from Department of Planning and Budget (SB527)
- 02/02/2026 - Senate: Rereferred from Commerce and Labor to Finance and Appropriations (11-Y 0-N)
- 02/02/2026 - Senate: Rereferred to Finance and Appropriations
- 02/10/2026 - Senate: Reported from Finance and Appropriations (14-Y 0-N)
